A multi-centre double-blind parallel-group randomised controlled study to investigate efficacy safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared to donepezil and placebo in patients with cognitive impairment due to Alzheimer's Disease
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to test the safety and effectiveness of 4 different doses of the study drug BI 409306 compared to donepezil and placebo, and to measure changes in memory and thinking skills.
Description
The purpose of this study is to test the safety and effectiveness of 4 different doses of the study drug BI 409306 compared to donepezil and placebo and measure changes in memory and thinking skills.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer's disease
-
Age: Between 55 Years - 100 Years
-
Gender: All
Updated on
26 Apr 2024.
Study ID: 1504462375
